Spyre Therapeutics, Inc. 8-K

What Happened

• On April 13, 2026 Spyre Therapeutics, Inc. announced it expects to report approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026. The company said these figures are preliminary, unaudited and subject to completion of financial close procedures.
• Also effective April 13, 2026, Spyre suspended and terminated the prospectus for its at‑the‑market (ATM) offering under the Sales Agreement with TD Securities (USA) LLC; the underlying Sales Agreement remains in effect but no sales will occur under the ATM unless a new prospectus or registration statement is filed.

Key Details

• Preliminary cash, cash equivalents and marketable securities: ~ $741 million as of March 31, 2026.
• Included in that amount: $30 million of legacy asset disposition proceeds collected in Q1 2026.
• Approximately $23 million of those proceeds are expected to be paid to holders of the company’s contingent value rights during Q2 2026.
• Company emphasized these amounts are unaudited and may differ materially from final results; no accounting firm has audited or reviewed the preliminary figures.

Why It Matters

• For investors, the reported $741M preliminary cash balance is the headline indicator of the company’s liquidity and ability to fund operations, R&D or corporate activities in the near term.
• The $23M expected payout related to contingent value rights reduces available cash and is a near‑term cash outflow to note.
• Suspending the ATM prospectus means Spyre cannot raise equity through that at‑the‑market program until a new prospectus/registration statement is filed, limiting one avenue for quick capital raises.
• Because the figures are preliminary and unaudited, investors should wait for the company’s completed quarterly financial statements for finalized numbers.